1
|
Whole blood or plasma: what is the ideal matrix for pharmacokinetic-driven drug candidate selection? Future Med Chem 2020; 13:157-171. [PMID: 33275044 DOI: 10.4155/fmc-2020-0187] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
In the present era of drug development, quantification of drug concentrations following pharmacokinetic studies has preferentially been performed using plasma as a matrix rather than whole blood. However, it is critical to realize the difference between measuring drug concentrations in blood versus plasma and the consequences thereof. Pharmacokinetics using plasma data may be misleading if concentrations differ between plasma and red blood cells (RBCs) because of differential binding in blood. In this review, factors modulating the partitioning of drugs into RBCs are discussed and the importance of determining RBC uptake of drugs for drug candidate selection is explored. In summary, the choice of matrix (plasma vs whole blood) is an important consideration to be factored in during drug discovery.
Collapse
|
2
|
Fluorescence Excitation-Emission Spectroscopy: An Analytical Technique to Monitor Drugs of Addiction in Wastewater. WATER 2019. [DOI: 10.3390/w11020377] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Emerging contaminants of concern have become a serious issue for the scientific community and society more broadly in recent years due to their increasingly widespread environmental distribution and largely unknown environmental and human health impacts. This study aimed to explore the use of fluorescence excitation-emission (F-EEM) spectroscopy as an alternative analytical method to evaluate the presence of key drugs of addiction (benzoylecgonine, methamphetamine, MDMA, codeine and morphine) in wastewater treatment plants. The chemicals of interest from wastewater were extracted by mixed-mode solid phase extraction and quantified using liquid chromatography tandem mass spectrometry. The same wastewater samples were also analysed by a fluorescence spectrophotometer for fluorescence spectra at wavelengths 280–600 nm (emission) and 200–600 nm (excitation). The study also investigated the relevance of different methods for interpreting F-EEM matrices data including parallel factor analysis (PARAFAC) modelling and fluorescence regional integration technique. PARAFAC identified four components, and among them, component C2, identified at the λex/λem = 275/340 nm wavelength associated with proteinaceous compounds most likely related to tryptophan amino acid, showed significant correlation with codeine removal. MDMA and morphine were not correlated to any of the fluorescence regions. The fluorescence regions related to aromatic protein-like fluorescence were correlated significantly with drug concentration and so may offer a suitable alternative approach for monitoring drugs including benzoylecgonine, methamphetamine and codeine.
Collapse
|
3
|
Shi P, Liao M, Chuang BC, Griffin R, Shi J, Hyer M, Fallon JK, Smith PC, Li C, Xia CQ. Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles. Xenobiotica 2018; 48:1173-1183. [PMID: 29098941 DOI: 10.1080/00498254.2017.1397812] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Revised: 10/23/2017] [Accepted: 10/24/2017] [Indexed: 01/13/2023]
Abstract
1. Red blood cell (RBC) partitioning is important in determining pharmacokinetic and pharmacodynamic properties of a compound; however, active transport across RBC membranes is not well understood, particularly without transporter-related cell membrane proteomics data. 2. In this study, we quantified breast cancer resistance protein (BCRP/Bcrp) and MDR1/P-glycoprotein (P-gp) protein expression in RBCs from humans, monkeys, dogs, rats and mice using nanoLC/MS/MS, and evaluated their effect on RBC partitioning and plasma exposure of their substrates. BCRP-specific substrate Cpd-1 and MDR1-specific substrate Cpd-2 were characterized using Caco-2 Transwell® system and then administered to Bcrp or P-gp knockout mice. 3. The quantification revealed BCRP/Bcrp but not MDR1/P-gp to be highly expressed on RBC membranes. The knockout mouse study indicated BCRP/Bcrp pumps the substrate out of RBCs, lowering its partitioning and thus preventing binding to intracellular targets. This result was supported by a Cpd-1 and Bcrp inhibitor ML753286 drug-drug interaction (DDI) study in mice. Because of enhanced partitioning of Cpd-1 into RBCs after BCRP/Bcrp inhibition, Cpd-1 plasma concentration changed much less extent with genetic or chemical knockout of Bcrp albeit marked blood concentration increase, suggesting less DDI effect. 4. This finding is fundamentally meaningful to RBC partitioning, pharmacokinetics and DDI studies of BCRP-specific substrates.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B/genetics
- ATP Binding Cassette Transporter, Subfamily B/metabolism
- ATP Binding Cassette Transporter, Subfamily G, Member 2/antagonists & inhibitors
- ATP Binding Cassette Transporter, Subfamily G, Member 2/genetics
- ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism
- Animals
- Caco-2 Cells
- Chromatography, Liquid
- Drug Interactions
- Erythrocyte Membrane/drug effects
- Erythrocyte Membrane/metabolism
- Female
- Humans
- Macaca fascicularis
- Mice, Inbred BALB C
- Mice, Knockout
- Neoplasm Proteins/antagonists & inhibitors
- Neoplasm Proteins/metabolism
- Rats
- Tandem Mass Spectrometry
- ATP-Binding Cassette Sub-Family B Member 4
Collapse
Affiliation(s)
- Pu Shi
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| | - Mingxiang Liao
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| | - Bei-Ching Chuang
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| | - Robert Griffin
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| | - Judy Shi
- b Cancer Pharmacology, Takeda Pharmaceuticals International Co , 40 Landsdowne Street, Cambridge, MA , USA , and
| | - Marc Hyer
- b Cancer Pharmacology, Takeda Pharmaceuticals International Co , 40 Landsdowne Street, Cambridge, MA , USA , and
| | - John K Fallon
- c Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill , NC , USA
| | - Philip C Smith
- c Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill , NC , USA
| | - Chao Li
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| | - Cindy Q Xia
- a Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co , 35 Landsdowne Street, Cambridge, MA , USA
| |
Collapse
|
4
|
Reyes-Garcés N, Alam MN, Pawliszyn J. The effect of hematocrit on solid-phase microextraction. Anal Chim Acta 2018; 1001:40-50. [DOI: 10.1016/j.aca.2017.11.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2017] [Revised: 10/10/2017] [Accepted: 11/01/2017] [Indexed: 01/13/2023]
|
5
|
Pellegatti M, Pagliarusco S, Solazzo L, Colato D. Plasma protein binding and blood-free concentrations: which studies are needed to develop a drug? Expert Opin Drug Metab Toxicol 2011; 7:1009-20. [DOI: 10.1517/17425255.2011.586336] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
6
|
Abstract
For about half a century, the binding of drugs to plasma albumin, the "silent receptor," has been recognized as one of the major determinants of drug action, distribution, and disposition. In the last decade, the binding of drugs, especially but not exclusively basic entities, to another plasma protein, alpha 1-acid glycoprotein (AAG), has increasingly become important in this regard. The present review points out that hundreds of drugs with diverse structures bind to this glycoprotein. Although plasma concentration of AAG is much lower than that of albumin, AAG can become the major drug binding macromolecule in plasma with significant clinical implications. Also, briefly reviewed are the physiological, pathological, and genetic factors that influence binding, the role of AAG in drug-drug interactions, especially the displacement of drugs and endogenous substances from AAG binding sites, and pharmacokinetic and clinical consequences of such interactions. It can be predicted that in the future, rapid automatic methods to measure binding to albumin and/or AAG will routinely be used in drug development and in clinical practice to predict and/or guide therapy.
Collapse
Affiliation(s)
- Z H Israili
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
| | | |
Collapse
|
7
|
Mazoit JX, Samii K. Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. Br J Clin Pharmacol 1999; 47:35-42. [PMID: 10073737 PMCID: PMC2014200 DOI: 10.1046/j.1365-2125.1999.00860.x] [Citation(s) in RCA: 123] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
AIMS Propofol is a widely used i.v. anaesthetic agent. However, its binding properties to blood components have not been fully studied. METHODS We studied the binding of propofol to erythrocytes, to human serum and to isolated serum proteins. Because propofol bound to ultrafiltration and equilibrium dialysis membranes, we used a co-binding technique with dextran coated charcoal and with erythrocytes. RESULTS Propofol free fraction in blood was 1.2-1.7% at total concentrations ranging from 2.80 to 179 microM (0.5 to 32 microg ml(-1)). Fifty percent was bound to erythrocytes and 48% to serum proteins, almost exclusively to human serum albumin. In the clinical range of concentrations (0.5-16 microg ml(-1)) 40% of the molecules bound to erythrocytes are on the red blood cells membranes. No binding to lipoproteins occurred and binding to alpha1-acid glycoprotein was less than 1.5% CONCLUSIONS We conclude that hypoalbuminaemia may increase propofol free fraction particularly during prolonged administration. Since propofol is non-restrictively cleared, no change in clearance is expected to occur, and the increase in free fraction will not be compensated by a parallel increase in clearance. It is also noted that many in vitro studies used concentrations 50 to 500 times the concentration expected to be encountered in the immediate cellular environment.
Collapse
Affiliation(s)
- J X Mazoit
- Laboratoire d'Anesthésie, Faculté de Médecine du Kremlin-Bicêtre, Université Paris-Sud, France
| | | |
Collapse
|
8
|
Reinoso RF, Telfer BA, Rowland M. In vitro studies of teicoplanin binding to rat tissues and erythrocytes. Eur J Pharm Sci 1998; 6:145-52. [PMID: 9925429 DOI: 10.1016/s0928-0987(97)00079-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Teicoplanin is a large polar antibiotic with a large distribution volume (Vss = 1.2-2.8 l/kg) despite extensive binding to plasma albumin. To understand this observation, binding of 3H-teicoplanin to 10% rat tissue homogenates was determined in vitro by ultracentrifugation in the presence of teicoplanin (1-30 microg/ml). Binding and efflux from erythrocytes were also studied. The in vitro total-to-unbound tissue concentration ratio (Kpu) differed widely but for each tissue was concentration independent. Upon correction for the plasma unbound fraction, there was discrepancy between the in vitro and in vivo tissue-to-plasma concentration ratios (KP), the latter calculated from previously published tissue and plasma concentration-time data using the area method. Moreover, calculation of Vss from in vitro Kp (8.10 l/kg) overestimated the in vivo value. These results suggest that in vivo teicoplanin binds to cell membranes and enters some but not all cells, such as erythrocytes.
Collapse
Affiliation(s)
- R F Reinoso
- School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK
| | | | | |
Collapse
|
9
|
Bailey DN. Effect of drugs and cocaine metabolites on cocaine and cocaethylene binding to human serum in vitro. Ther Drug Monit 1997; 19:427-30. [PMID: 9263384 DOI: 10.1097/00007691-199708000-00011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The effect of amphetamine (AMPH), codeine (COD), methamphetamine (MEPH), morphine (MORP), and benzoylecgonine (BE) on the binding of cocaethylene (CE) and cocaine (COC) to human serum in vitro was investigated by equilibrium dialysis at 4 degrees C. Each compound was added individually at concentrations of 500, 1,000, or 2,000 nM to pooled human serum containing COC or CE at 500 nM concentration. For COC, the addition of COD, MEPH, and CE enhanced serum binding whereas MORP and BE decreased it. Variable effects on COC binding were noted for AMPH. For CE, the addition of COD and COC generally increased binding whereas MORP decreased it. No appreciable effect on CE binding was observed after adding AMPH, MEPH, and BE. Except for CE, AMPH, and MEPH in the presence of COC, the binding of COC and CE tended to be less with 2,000 nM of each added drug than at lower concentrations of them, presumably because of mass-action displacement of COC and CE at the higher concentration. These findings should be clinically important because these drugs are frequently found together in patients.
Collapse
Affiliation(s)
- D N Bailey
- Department of Pathology, University of California, San Diego Medical Center 92103-8320, USA
| |
Collapse
|
10
|
Abstract
The plasma protein binding of drugs has been shown to have significant effects on numerous aspects of clinical pharmacokinetics and pharmacodynamics. In many clinical situations, measurement of the total drug concentration does not provide the needed information concerning the unbound fraction of drug in plasma which is available for distribution, elimination, and pharmacodynamic action. Thus, accurate determination of unbound plasma drug concentrations is essential in the therapeutic monitoring of drugs. Many methodologies are available for determining the extent of plasma protein binding of drugs, however, in the clinical evaluation of drug therapy, equilibrium dialysis and ultrafiltration are the most routinely utilised methods. Both of these methods have been proven to be experimentally sound and to yield adequate protein binding data. Furthermore, the characterisation of the interactions between drug and protein molecules is essential for the assessment of the pharmacokinetic implications of drug-protein binding. Protein binding parameters which characterise the affinity of the drug-protein association, the number of classes of binding sites, the number of binding sites per class or protein and the binding capacity are useful for predicting unbound drug concentrations. Simple graphical methods have often been used to obtain protein binding parameters, but these methods have limitations and are not useful for drugs with more than 1 class of binding site. Therefore, the fitting of protein binding models which characterise the drug-protein binding interaction for experimental data is the preferred method of calculating binding parameters. Using the appropriate model, values for binding parameters are typically estimated by using nonlinear least-squares regression analysis.
Collapse
Affiliation(s)
- J D Wright
- Department of Pharmaceutics, College of Pharmacy, University of Georgia, Athens, USA
| | | | | |
Collapse
|